文献速递肝病

布鲁维肽反应指导的慢性丁型肝炎患者长期治疗——一项真实世界研究结果

Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.
PubMed 文献 · Aliment Pharmacol Ther · 2022-05-05

本研究为真实世界研究,23例慢性丁型肝炎患者接受布鲁维肽单药治疗,其中22例完成至少24周治疗。第24周10例(45%)为布鲁维肽应答者;8例加用聚乙二醇干扰素后HDV-RNA均下降。长期布鲁维肽单药治疗安全有效,可降低HDV-RNA和ALT,即使在肝硬化患者中亦如此。布鲁维肽单用或联合聚乙二醇干扰素的最佳疗程尚待确定。

要点

  • 布鲁维肽单药治疗在45%(10/22)患者第24周达到应答。
  • 加用聚乙二醇干扰素后8例患者HDV-RNA均下降,12周内平均下降1.29±0.19 log。
  • 第24、36、48、60周HDV-RNA下降>2log或检测不到的比例分别为45%、55%、65%、69%。

核心结论

  • 长期布鲁维肽单药治疗安全,并能有效降低HDV-RNA和ALT,即使在肝硬化患者中亦如此。
  • 布鲁维肽单药治疗或联合聚乙二醇干扰素的最佳疗程尚待确定。
  • 作者提出了反应指导的布鲁维肽治疗流程算法。

研究设计与样本

  • 真实世界研究,23例慢性丁型肝炎患者接受布鲁维肽单药治疗(2 mg/天:22例;10 mg/天:1例)。
  • 患者为男性10例、女性13例;平均年龄47.9岁;肝硬化16例;中位ALT 71 IU/ml;中位HDV-RNA 2.1×10^5 copies/ml。
  • 22例完成至少24周治疗(24–137周)。
  • 第24周后HDV-RNA未见进一步下降的患者以反应指导方式加用聚乙二醇干扰素。

主要发现

  • 第24周10例(45%)被归类为布鲁维肽应答者。
  • 2例在HDV-RNA检测不到>6个月后停用布鲁维肽,但两者均再次转为HDV-RNA阳性。
  • 1例在第25周接受肝移植;1例因副作用在第60周终止治疗;10例仍在布鲁维肽单药治疗中。
  • 8例加用聚乙二醇干扰素后所有患者HDV-RNA均下降,12周内平均下降1.29±0.19(SD)log。
  • 第24、36、48、60周HDV-RNA下降>2log或检测不到的比例分别为45%(10/22)、55%(11/20)、65%(13/20)、69%(9/13);ALT正常化比例分别为64%(14/22)、85%(17/20)、90%(18/20)、92%(12/13)。

临床怎么用

  • 作者提出了反应指导的布鲁维肽治疗流程算法。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: Bulevirtide (BLV) blocks the uptake of the hepatitis D virus (HDV) into hepatocytes via the sodium/bile acid cotransporter NTCP. BLV was conditionally approved by the EMA but real-life data on BLV efficacy are limited. METHODS: Patients were treated with BLV monotherapy. Patients who did not achieve further decreases in HDV-RNA after 24 weeks were offered PEG-IFN as an add-on therapy in a response-guided manner. RESULTS: Twenty-three patients (m: 10, f: 13; mean age: 47.9 years, cirrhosis: 16; median ALT: 71 IU/ml; median HDV-RNA: 2.1 × 105 copies/ml) started BLV monotherapy (2 mg/day: 22; 10 mg/day: 1). Twenty-two completed ≥24 weeks of treatment (24-137 weeks): Ten (45%) were classified as BLV responders at week 24. BLV was stopped in two patients with >6 months HDV-RNA undetectability, but both became HDV-RNA positive again. One patient was transplanted at week 25. One patient terminated treatment because of side effects at week 60. Ten patients are still on BLV monotherapy. Adding PEG-IFN in eight patients induced an HDV-RNA decrease in all (1.29 ± 0.19 [SD] log within 12 weeks). HDV-RNA decreased by >2log or became undetectable in 45%(10/22), 55%(11/20), 65% (13/20) and 69% (9/13); and ALT levels normalised in 64% (14/22), 85% (17/20), 90% (18/20) and in 92% (12/13) patients at weeks 24, 36, 48 and 60, respectively. Portal pressure decreased in 40% (2/5) of patients undergoing repeated measurement under BLV therapy. CONCLUSION: Long-term BLV monotherapy is safe and effectively decreases HDV-RNA and ALT-even in patients with cirrhosis. The optimal duration of BLV treatment alone or in combination with PEG-IFN remains to be established. An algorithm for a response-guided BLV treatment approach is proposed.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jachs M, Schwarz C, Panzer M, et al. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study. Aliment Pharmacol Ther. 2022. PMID: 35514008. doi:10.1111/apt.16945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。